These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16619108)

  • 41. ACE inhibitors and high-risk patients.
    Myers KA
    CMAJ; 2000 Aug; 163(3):327. PubMed ID: 10951738
    [No Abstract]   [Full Text] [Related]  

  • 42. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context.
    Ferrari R; Rosano GM
    Int J Cardiol; 2013 Jun; 166(2):286-8. PubMed ID: 23452882
    [No Abstract]   [Full Text] [Related]  

  • 43. ACE inhibitors--revisited.
    Sathyamurthy I; Jayanthi K
    J Assoc Physicians India; 2000 Jul; 48(7):715-8. PubMed ID: 11273508
    [No Abstract]   [Full Text] [Related]  

  • 44. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
    Rabinowitz I; Tamir A
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
    Ferrari R; Guardigli G; Ceconi C
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):331-9. PubMed ID: 20577898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M
    Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Angiotensin-I converting enzyme].
    Nakai K; Syoh T; Hiramori K
    Nihon Rinsho; 1995 May; 53(5):1232-6. PubMed ID: 7602784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. US guidelines on secondary prevention of cardiovascular disease updated.
    Bradbury J
    Lancet; 2001 Sep; 358(9287):1074. PubMed ID: 11589949
    [No Abstract]   [Full Text] [Related]  

  • 56. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
    McAlister FA;
    Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?
    Hammett DC; MacFadyen JC
    Can Fam Physician; 2000 Apr; 46():821-3. PubMed ID: 10790814
    [No Abstract]   [Full Text] [Related]  

  • 58. ACE inhibition in cardiovascular disease.
    Francis GS
    N Engl J Med; 2000 Jan; 342(3):201-2. PubMed ID: 10639547
    [No Abstract]   [Full Text] [Related]  

  • 59. ACE inhibitors and cardiovascular protection in diabetes.
    Donnelly R
    Diabetes Obes Metab; 2004 Nov; 6(6):399-401. PubMed ID: 15479215
    [No Abstract]   [Full Text] [Related]  

  • 60. [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):121-4. PubMed ID: 10769584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.